Market closed
Insmed/$INSM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Insmed
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Ticker
$INSM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
912
Website
Insmed Metrics
BasicAdvanced
$13B
Market cap
-
P/E ratio
-$5.56
EPS
1.11
Beta
-
Dividend rate
Price and volume
Market cap
$13B
Beta
1.11
52-week high
$80.53
52-week low
$21.92
Average daily volume
1.4M
Financial strength
Current ratio
6.365
Quick ratio
5.827
Long term debt to equity
237.769
Total debt to equity
239.942
Interest coverage (TTM)
-8.45%
Management effectiveness
Return on assets (TTM)
-26.05%
Return on equity (TTM)
-890.75%
Valuation
Price to revenue (TTM)
33.161
Price to book
27.06
Price to tangible book (TTM)
41.34
Price to free cash flow (TTM)
-17.881
Growth
Revenue change (TTM)
22.13%
Earnings per share change (TTM)
5.62%
3-year revenue growth (CAGR)
25.44%
3-year earnings per share growth (CAGR)
12.37%
What the Analysts think about Insmed
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Insmed stock.
Insmed Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Insmed Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Insmed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Insmed stock?
Insmed (INSM) has a market cap of $13B as of November 24, 2024.
What is the P/E ratio for Insmed stock?
The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of November 24, 2024.
Does Insmed stock pay dividends?
No, Insmed (INSM) stock does not pay dividends to its shareholders as of November 24, 2024.
When is the next Insmed dividend payment date?
Insmed (INSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Insmed?
Insmed (INSM) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.